



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/825,769	04/04/2001	Milan S. Blake	NV1932	3657

7590 02/06/2003

Baxter Healthcare Corporation  
P.O. Box 15210  
Irvine, CA 92614

EXAMINER

FORD, VANESSA L

ART UNIT	PAPER NUMBER
1645	13

DATE MAILED: 02/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER 09/825,769	FILING DATE 04/04/2001	FIRST NAMED APPLICANT Blake et al.	ATTORNEY DOCKET NO. NV1932
			EXAMINER
			Ford, Vanessa
			ART UNIT 1645 PAPER 12


DATE MAILED:

**Please find below a communication from the EXAMINER in charge of this application**

1. This Application contains sequences disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.8221(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements for Patent Applications Containing Nucleotide Sequences And/Or Amino Acid Sequence Disclosures.
2. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136. In no case may an applicant extend the period for response beyond the six months statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.
3. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.
4. Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989). Should applicant wish to FAX a response, the current Fax number for Group 1600 is (703) 308-4242.

Any inquiry concerning this communication should be directed to Patent Examiner Vanessa Ford, Art Unit 1645 at (703) 308-4735. If attempts to reach the examiner by phone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (703) 308-3909. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice To Comply.

  
Vanessa L. Ford  
Patent Examiner, Group 1600  
Art Unit 1645

  
JAMES O. WILSON  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR §1.821 - §1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 CFR §1.821 - §1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR §1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR §1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR §1.822 and/or §1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR§1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR §1.821(e).
- 7. Other: The Applicant's CRF and sequence listing does not contain the DNA sequences disclosed in Figure 7 of the specification. The specification needs to be amended to included sequence identifiers for the DNA sequence(s) in Figure 7.

**APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as were as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

For Rules Interpretation, call (703) 308-1123  
For CRF Submission help, call (703)308-4212  
For Patentin Software help, call (703) 557-0400

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE.**